Ublituximab Quite ‘Reassuring’ as Potential MS Therapy, Experts Say

Ublituximab Quite ‘Reassuring’ as Potential MS Therapy, Experts Say

298080

Ublituximab Quite ‘Reassuring’ as Potential MS Therapy, Experts Say

In clinical trials, the investigational anti-CD20 therapy ublituximab was the first to push the annualized relapse rate (ARR) below the 0.1 threshold among patients with relapsing forms of multiple sclerosis (MS), while improving disability outcomes in a significant proportion of patients. “The [relapse] rate was below a tenth of a relapse a year, and this had been a barrier that hadn’t been [crossed],” Lawrence Steinman, MD, a professor of neurology at Stanford University, said in…

You must be logged in to read/download the full post.